29
total announcements
INDOCO.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 29 Oct 2026
Market Cap
₹1,970 Cr
P/E (TTM)
668.0
P/E (Forward)
19.4
EPS (TTM)
₹0.32
52W Low
₹162.19
52W High
₹288.00
Dividend Yield
0.09%
Beta
0.62
Price / Book
1.9
Return on Equity
3.19%
Debt / Equity
104.3
Revenue (TTM)
₹1,909 Cr
Gross Margin
64.93%
Operating Margin
2.31%
Indoco Remedies Ltd
Indoco Remedies Ltd has published unaudited standalone and consolidated financial results for the quarter and half year ended 30-09-2026, showing a net profit of Rs. 3,063 lakhs and a total income of Rs. 45,159 lakhs.
Indoco Remedies Ltd
Indoco Remedies Ltd has made available the audio recording of its earnings conference call for the quarter and half year ended 30th September, 2026, on its website.
Indoco Remedies Ltd
Indoco Remedies Ltd's Clinical Research Organisation, AnaCipher, has received approval from ANVISA Brazil for its clinical and bioanalytical facilities.
Indoco Remedies Ltd
Indoco Remedies Ltd has approved its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026, with revenue from operations at Rs. 43,806 lakhs and net profit at Rs. 1,08,073 lakhs.
Indoco Remedies Ltd
Indoco Remedies Ltd has announced its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026, with revenue from operations at Rs. 43,806 lakhs and net profit at Rs. 1,08,073 lakhs.
Indoco Remedies Ltd
Indoco Remedies Ltd has informed the exchange about the allotment of 14,850 equity shares to the Indoco Employees Welfare Trust under the Indoco Remedies Limited Employee Stock Option Plan - 2022.
Indoco Remedies Ltd
Indoco Remedies Ltd has announced an earnings conference call for Q2 FY2026-2027, scheduled for October 27, 2026, to discuss unaudited financial results for the quarter and half year ended September 30, 2026.
Indoco Remedies Ltd
Indoco Remedies Ltd has scheduled a board meeting on 27th October 2026 to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended 30th September 2026.
Indoco Remedies Ltd
Indoco Remedies Ltd has attached a certificate confirming compliance under Regulation 74(5) of SEBI(D & P) Regulations,2018 for the quarter ended 30-09-2026.
Indoco Remedies Ltd
Indoco Remedies Ltd has issued a notice to shareholders holding shares in physical mode, requesting them to furnish their PAN, KYC, and bank details as per SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026. The company has also informed that transfer of shares in physical form is not permitted w.e.f. April 01, 2019, and shareholders are requested to convert their shares from physical form to demat form at the earliest possible.
Indoco Remedies Ltd
Indoco Remedies Ltd has incorporated a wholly owned subsidiary, Warren Lifesciences Private Limited, under the Companies Act, 2013. The subsidiary has an authorized share capital of Rs. 1,00,000 divided into 10,000 equity shares of Rs. 10 each. The subsidiary will manufacture, develop, and sell pharmaceutical products.
Indoco Remedies Ltd
Indoco Remedies Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Indoco Remedies Ltd
Indoco Remedies Ltd has been assigned an ESG rating of 'Crisil ESG 60' by Crisil ESG Ratings & Analytics Limited, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Indoco Remedies Ltd
Indoco Remedies Ltd received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the purchase of 4,000 equity shares from the Open Market by Aditi M. Panandikar and Madhura Suresh Kare.
Indoco Remedies Ltd
Aditi M. Panandikar and Madhura Suresh Kare have acquired 10,000 shares of Indoco Remedies Ltd through the open market, increasing their combined stake to 5.86%.
Indoco Remedies Ltd
Indoco Remedies Ltd has executed a Deed of Conveyance for the sale of its plot of land to Kalpataru Townships Private Limited for Rs. 64,00,00,000. The sale will not impact the company's business operations.
Indoco Remedies Ltd
Indoco Remedies Ltd has announced the 79th Annual General Meeting (AGM) and e-voting information, with the meeting to be held on September 17, 2026, through video conferencing or other audio-visual means. The company has sent the annual report and notice of AGM to members via email and has made it available on its website and on the websites of the stock exchanges.
Indoco Remedies Ltd
Indoco Remedies Ltd has submitted its Business Responsibility and Sustainability Report for the financial year 2025-2026, as per SEBI regulations. The report highlights the company's corporate identity, business activities, operations, employees, and sustainability initiatives.
Indoco Remedies Ltd
Indoco Remedies Ltd has announced its Annual Report for the financial year 2025-2026, along with the Notice of the 79th Annual General Meeting (AGM). The report includes financial highlights, corporate governance information, and details of the AGM schedule.
Indoco Remedies Ltd
Indoco Remedies Ltd has announced the notice of its 79th Annual General Meeting (AGM) and Annual Report for the financial year 2025-2026. The AGM will be held on September 17, 2026, via video conference and other audio-visual means. The company has also uploaded the Annual Report on its website at www.indoco.com.